Senseonics' FDA-approved CGM has a sensor that lasts six months, a first for any CGM. Other competing solutions from Medtronic and Dexcom last anywhere between three to 10 days.
ViVE 2022, powered by HLTH and CHIME, will convene top thought leaders who are shaping tech-enabled healthcare and addressing key issues in digital health innovation. Save $150 with code medcity150!
We are extending our INVEST 2022 Pitch Perfect deadline to Feb 11, 11:59 p.m. ET to allow interested startups to apply to the 4 tracks - PharmaTech, Diagnostics 2.0, Care Coordination and Value-Based Care, and Remote Patient Monitoring and Smart Devices. Slots are going fast so we encourage all startups - particularly those interested to apply in the PharmaTech and Diagnostics tracks to apply immediately. Selected startups will get to pitch LIVE on stage in front of VC judges. Here's the agenda for the INVEST conference.
By Michael Schroeder Monday, February 14, 2022 7:54 PM
Senseonics' FDA-approved CGM has a sensor that lasts six months, a first for any CGM. Other competing solutions from Medtronic and Dexcom last anywhere between three to 10 days.
Chief Data Scientist at SecureLink discusses a disturbing phenomenon: medical professionals sifting through patient records to find information on potential dates.
By Frank Vinluan Monday, February 14, 2022 1:16 PM
An Eisai drug that produced disappointing data in a myelodysplastic syndrome study is getting another shot under a newly launched Roivant Sciences subsidiary, Hemavant. Roivant executives say the small molecule could be a safer, more effective alternative to MDS therapies marketed by Bristol Myers Squibb.
By Adam Dakin and Mike Ravenscroft Monday, February 14, 2022 11:51 AM
Our survey of health system CIOs finds growing demand for platforms that not only solve big and urgent problems but deliver provable ROI and integrate with existing workflows. Despite this high bar, investors are deploying record amounts of capital to startups with big dreams and few proof points.
No comments